C4 Therapeutics, Inc.
For the period ended Mar 31, 2025. Filed May 7, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 7, 2025
CCCC$3.15+1.6%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets
(in thousands, except share and per share amounts)
| March 31,2025 | December 31,2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $51,293 | $55,499 |
| Marketable securities, current | 163,794 | 189,405 |
| Accounts receivable | 8,028 | 3,102 |
| Prepaid expenses and other current assets | 9,420 | 9,761 |
| Total current assets | 232,535 | 257,767 |
| Marketable securities, non-current | 19,619 | 22,359 |
| Property and equipment, net | 5,478 | 5,842 |
| Right-of-use asset | 55,886 | 57,536 |
| Restricted cash | 3,443 | 3,443 |
| Other assets | 2,563 | 2,655 |
| Total assets | $319,524 | $349,602 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $683 | $1,328 |
| Accrued expenses and other current liabilities | 12,633 | 19,363 |
| Deferred revenue, current | 21,585 | 18,712 |
| Operating lease liability, current | 5,919 | 5,774 |
| Total current liabilities | 40,820 | 45,177 |
| Deferred revenue, net of current | 25,117 | 28,457 |
| Operating lease liability, net of current | 58,447 | 59,982 |
| Total liabilities | 124,384 | 133,616 |
| Commitments and contingencies (see Note 11) | ||
| Stockholders’ equity: | ||
| Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized, and no shares issued or outstanding as of March 31, 2025 and December 31, 2024, respectively | — | — |
| Common stock, par value of $0.0001 per share; 150,000,000 shares authorized, and 70,989,661 and 70,625,899 shares issued and outstanding as of March 31, 2025 and December 31, 2024, respectively | 7 | 7 |
| Additional paid-in capital | 855,111 | 849,625 |
| Accumulated other comprehensive income (loss) | 43 | 53 |
| Accumulated deficit | (660,021) | (633,699) |
| Total stockholders’ equity | 195,140 | 215,986 |
| Total liabilities and stockholders’ equity | $319,524 | $349,602 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.